Back to Search Start Over

Aberrant expression of junctional adhesion molecule‐A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155.

Authors :
Murakami, Taro
Takasawa, Akira
Takasawa, Kumi
Akimoto, Taishi
Aoyama, Tomoyuki
Magara, Kazufumi
Saito, Yuki
Ota, Misaki
Kyuno, Daisuke
Yamamoto, Soh
Hasegawa, Tadashi
Saito, Tsuyoshi
Osanai, Makoto
Source :
Cancer Science; Feb2021, Vol. 112 Issue 2, p906-917, 12p
Publication Year :
2021

Abstract

Recent studies have shown that aberrant expression of tight junction proteins (TJP) contributes to malignant potential of various cancers. In the present study, we investigated the expression of junctional adhesion molecule‐A (JAM‐A), one of the transmembrane TJP, in uterine cervical adenocarcinoma and the significance of its expression for malignancy. Immunohistochemistry on human surgical specimens showed that JAM‐A was aberrantly expressed in neoplastic regions including adenocarcinoma in situ (AIS). Knockout of JAM‐A significantly suppressed cell proliferation and colony‐forming and migration abilities. We also showed that an antibody specific to an extracellular region of JAM‐A reduced cell proliferation ability and that loss of JAM‐A increased drug sensitivity of cervical adenocarcinoma cells. Based on a comprehensive proteome analysis, we found that poliovirus receptor (PVR/CD155) was regulated by JAM‐A and formed a physical interaction with JAM‐A. In human surgical specimens, PVR/CD155 expression was significantly correlated with some clinicopathological features and prognosis of cervical adenocarcinoma. Interestingly, most of the PVR/CD155‐positive cases expressed a high level of JAM‐A, and patients with the expression pattern of PVR/CD155 positive/JAM‐A high had significantly shorter periods of relapse‐free survival (P =.00964) and overall survival (P =.0204) than those for the other patients. Our observations suggest that aberrant expression of JAM‐A promotes malignancy of uterine cervical adenocarcinoma by regulation of PVR/CD155, and JAM‐A is therefore a potential therapeutic target for this malignancy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13479032
Volume :
112
Issue :
2
Database :
Complementary Index
Journal :
Cancer Science
Publication Type :
Academic Journal
Accession number :
148861772
Full Text :
https://doi.org/10.1111/cas.14734